Ilyang Pharmaceutical Co.,Ltd

KOSE:A007570 Stock Report

Market Cap: ₩199.0b

Ilyang PharmaceuticalLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ilyang PharmaceuticalLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth31.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Apr 04
Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Should You Be Adding Ilyang PharmaceuticalLtd (KRX:007570) To Your Watchlist Today?

Mar 14
Should You Be Adding Ilyang PharmaceuticalLtd (KRX:007570) To Your Watchlist Today?

Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

Mar 14
Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

Declining Stock and Decent Financials: Is The Market Wrong About Ilyang Pharmaceutical Co.,Ltd (KRX:007570)?

Feb 22
Declining Stock and Decent Financials: Is The Market Wrong About Ilyang Pharmaceutical Co.,Ltd (KRX:007570)?

Did Business Growth Power Ilyang PharmaceuticalLtd's (KRX:007570) Share Price Gain of 159%?

Feb 01
Did Business Growth Power Ilyang PharmaceuticalLtd's (KRX:007570) Share Price Gain of 159%?

Is Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) Shareholder Ownership Skewed Towards Insiders?

Jan 11
Is Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) Shareholder Ownership Skewed Towards Insiders?

Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

Dec 24
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

Dec 06
A Look At The Intrinsic Value Of Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 18
Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ilyang PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSE:A007570 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024364,562-738-30,3832,273N/A
6/30/2024366,05364212,29531,889N/A
3/31/2024368,707-3,35814,31727,357N/A
12/31/2023370,537-2,4677,37719,382N/A
9/30/2023367,4325,5064,70213,915N/A
6/30/2023380,6548,435-1,00418,573N/A
3/31/2023378,43715,67875219,634N/A
12/31/2022383,81118,7899,40129,936N/A
9/30/2022389,45421,26026,55046,428N/A
6/30/2022376,53921,23442,94156,925N/A
3/31/2022374,95720,00946,81161,030N/A
12/31/2021371,34814,38445,84867,020N/A
9/30/2021351,56211,55946,17171,174N/A
6/30/2021353,2658,72740,71767,915N/A
3/31/2021353,7718,04528,66361,880N/A
12/31/2020343,32910,88032,86257,484N/A
9/30/2020336,95410,55828,06849,820N/A
6/30/2020324,1429,48717,24732,683N/A
3/31/2020319,2428,49319,61628,616N/A
12/31/2019324,5739,98527,80736,193N/A
9/30/2019323,1117038,78321,110N/A
6/30/2019311,322-5,13815,77326,281N/A
3/31/2019304,435-4,82117,95029,159N/A
12/31/2018300,036-4,89312,44222,120N/A
9/30/2018289,4606,97027,49433,742N/A
6/30/2018291,9748,474N/A26,732N/A
3/31/2018282,4629,139N/A34,329N/A
12/31/2017269,8116,265N/A30,025N/A
9/30/2017262,2144,475N/A24,738N/A
6/30/2017262,3236,101N/A31,557N/A
3/31/2017263,1595,206N/A25,324N/A
12/31/2016261,6155,848N/A26,982N/A
12/31/2015239,2634,409N/A40,272N/A
9/30/2015237,556-2,266N/A32,968N/A
6/30/2015226,844-4,442N/A28,921N/A
3/31/2015211,798-10,962N/A18,629N/A
12/31/2014195,872-9,193N/A5,162N/A
9/30/2014179,412-5,320N/A-3,066N/A
6/30/2014158,829-530N/A-10,789N/A
3/31/2014147,7323,963N/A-3,036N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A007570's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A007570's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A007570's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A007570's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A007570's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A007570's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 18:12
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ilyang Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Jae Hoon ShinLS Securities Co., Ltd.
Jaechul ParkMirae Asset Securities Co., Ltd. (Pre-Merger)